1119 Syncona Purespring
BioCentury & Getty Images

Finance

Syncona enters kidney disease space with gene therapy newco Purespring

Firm launches sixth gene therapy start-up with £45M to reach clinic

Syncona’s Purespring pushes gene therapy beyond monogenic disorders in kidney diseases.

Nov 19, 2020 | 8:41 PM GMT

The launch of Purespring Therapeutics marks the next phase of Syncona’s strategy in moving gene therapy from targeting rare monogenic diseases to more

Read the full 640 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE